{"ATC Code":"N - Nervous system","Abbreviation":"Vyvanse","Actives":["Lysine","Dextroamphetamine"],"Aliases":["Lisdexamfetamine","lysine-d-amphetamine","lisdexanfetamina","lysine-dextroamphetamine","(2S)-2,6-Diamino-N-((1S)-1-methyl-2-phenylethyl)hexanamide","(2S)-2,6-Diamino-N-[(1S)-1-methyl-2-phenylethyl]hexanamide","(2S)-2,6-diamino-N-((2S)-1-phenylpropan-2-yl)hexanamide","lisdexamfetaminum","(2S)-2,6-diamino-N-((2S)-1-phenylpropan-2-yl)hexanimidic acid","(2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanimidic acid","N06BA12","GTPL7213","DB01255","D08130","N-[(1S)-1-Methyl-2-phenylethyl]-L-lysinamide","Q6558704","Hexanamide, 2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl]-, (2S)-"],"Biological Half-Life":"Plasma concentrations of unconverted lisdexamfetamine are low and transient, generally becoming non-quantifiable by 8 hours after administration. The plasma elimination half-life of lisdexamfetamine typically averaged less than one hour in volunteers ages six years and older. The plasma elimination half-life of dextroamphetamine was approximately 8.6 to 9.5 hours in pediatric patients six to 12 years and 10 to 11.3 hours in healthy adults.","CAS":"608137-32-2","ChEBI":"CHEBI:135925","ChEMBL":"CHEMBL1201222","ChemicalClasses":["amphetamine"],"Chirality":"achiral","Classes":["Codrug","Prodrug","Stimulant"],"Color/Form":"Golden-colored solid from methanol","Drug Classes":"Breast Feeding; Lactation; Milk, Human; Adrenergic Agents; Central Nervous System Stimulants; Dopamine Agents; Sympathomimetics; Wakefulness-Promoting Agents","Drug Indication":"Lisdexamfetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients six years and older. It is also indicated to treat moderate to severe binge eating disorder (BED) in adults. It is approved for use in the US and Canada.","Drug Warnings":"/BOX WARNING/ CNS stimulants (amphetamines and methylphenidate-containing products), including Vyvanse, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.","Erowid Experience Reports":null,"Esters":[],"FDA Pharmacological Classification":"H645GUL8KJ","Flash Point":"9.7 °C; 49.5 °F (closed cup)","Formating":[],"HMDB ID":"HMDB0015385","HeavyAtomCount":19,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Adrenergic Agents; Central Nervous System Stimulants; Dopamine Agents; Sympathomimetics; Wakefulness-Promoting Agents","IUPACName":"(2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide","InChI":"InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1","InChIKey":"VOBHXZCDAVEXEY-JSGCOSHPSA-N","MeSH Pharmacological Classification":"A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)","Melting Point":"191-193","MolecularFormula":"C\u003csub\u003e15\u003c/sub\u003eH\u003csub\u003e25\u003c/sub\u003eN\u003csub\u003e3\u003c/sub\u003eO","MolecularWeight":"263.38 g/mol","Pharmacodynamics":"Once administered, lisdexamfetamine is converted to its active metabolite, dextroamphetamine, which is taken up by the brain. Dextroamphetamine blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space. The parent drug, lisdexamfetamine, does not bind to the sites responsible for the reuptake of norepinephrine and dopamine in vitro.","Physical Description":"Solid","PubChemId":11597698,"RefCount":2,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Eticyclidine","Name":"Lisdexamphetamine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB01255","Name":"Lisdexamphetamine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/11597698","Name":"Lisdexamphetamine","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201222","Name":"Lisdexamphetamine","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:135925","Name":"Lisdexamphetamine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=608137-32-2","Name":"Lisdexamphetamine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0015385","Name":"Lisdexamphetamine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D08130","Name":"Lisdexamphetamine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/H645GUL8KJ","Name":"Lisdexamphetamine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID00209652","Name":"Lisdexamphetamine","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 11597698, Lisdexamphetamine. Accessed July 22, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/11597698\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/11597698\u003c/a\u003e"],"SMILES":"C[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)N","SaltData":[],"Salts":[],"Solubility":"White to off-white powder. MP 120-122 °C. Solubility in water: 792 mg/mL /Lisdexamfetamine dimethanesulfonate/","Stability/Shelf Life":"Stable under recommended storage conditions.","StereoisomerData":[],"Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 168.733 49.776\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#3050f8\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h169v50H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath fill=\"#000\" stroke=\"none\" d=\"M54.186 25.87h-.7l-1.75 15.24h4.2z\" class=\"bond\"/\u003e\u003cpath d=\"m53.836 25.87-13.198-7.62M40.638 18.25 27.44 25.87\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.44 25.87-13.204-7.629M25.002 27.277l-10.766-6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m14.236 18.241-13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.038 25.861.005 15.249M3.477 27.269l.004 12.433\"/\u003e\u003c/g\u003e\u003cpath d=\"m1.043 41.11 13.203 7.628\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m14.246 48.738 13.198-7.62M14.247 45.922l10.759-6.211\"/\u003e\u003c/g\u003e\u003cpath d=\"m27.44 25.87.004 15.248M53.836 25.87l10.045-5.8M70.187 20.07l10.045 5.8\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M81.452 25.166v12.022M79.013 25.166v12.022\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"M81.452 37.188v-6.011M79.013 37.188v-6.011\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m80.232 25.87 13.199-7.62M93.431 18.25l13.198 7.62M106.629 25.87l13.198-7.62M119.827 18.25l13.198 7.62M133.025 25.87l13.199-7.62M146.224 18.25l10.044 5.799M93.431 18.25V7.19\" class=\"bond\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M68.975 20.699h-.72l-2.62-4.066h-.03l.03.596q.024.357.024.732v2.738h-.566V15.8h.715l2.607 4.054h.03l-.018-.327-.024-.477q-.006-.262-.006-.482V15.8h.578zM68.838 15.238h-.619v-2.286h-2.512v2.286h-.614v-4.899h.614v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cpath fill=\"#ff0d0d\" stroke=\"none\" d=\"M82.492 41.107q0 .756-.256 1.327-.256.566-.756.881t-1.245.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.733 0 1.233.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .922.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M161.362 28.319h-.72l-2.619-4.066h-.03l.03.596q.024.357.024.732v2.738h-.566V23.42h.714l2.608 4.054h.03l-.018-.327-.024-.477q-.006-.262-.006-.482V23.42h.577zM165.669 28.319h-.619v-2.286h-2.513v2.286h-.613V23.42h.613v2.072h2.513V23.42h.619zM168.173 29.809h-1.943v-.3l.772-.779q.221-.221.371-.393.154-.175.233-.339.078-.168.078-.364 0-.243-.146-.368-.143-.129-.372-.129-.214 0-.378.075-.161.075-.329.207l-.193-.243q.172-.146.393-.246.225-.1.507-.1.411 0 .65.207t.24.575q0 .229-.097.432-.093.2-.264.397-.168.196-.393.418l-.614.603v.018h1.485z\"/\u003e\u003c/g\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M95.371 5.459h-.72l-2.619-4.066h-.03l.03.596q.023.357.023.732v2.738h-.565V.56h.714l2.608 4.054h.03l-.018-.327-.024-.477q-.006-.262-.006-.482V.56h.577zM99.678 5.459h-.62V3.173h-2.512v2.286h-.613V.56h.613v2.072h2.512V.56h.62zM102.182 6.949h-1.943v-.3l.772-.779q.221-.221.371-.393.154-.175.232-.339.079-.168.079-.364 0-.243-.146-.368-.143-.129-.372-.129-.214 0-.379.075-.16.075-.328.207l-.193-.243q.171-.146.393-.246.225-.1.507-.1.411 0 .65.207t.239.575q0 .229-.096.432-.093.2-.264.397-.168.196-.393.418l-.615.603v.018h1.486z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"#3050f8\" d=\"m63.881 20.07-5.023 2.9M63.881 20.07l-5.023 2.9M70.187 20.07l5.022 2.9M70.187 20.07l5.022 2.9M156.268 24.049l-5.022-2.9M93.431 7.19v5.53M93.431 7.19v5.53\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Subjective Effects":{"Cognitive Effects":["Analysis enhancement","Ego inflation","Focus enhancement","Increased music appreciation","Motivation enhancement","Thought acceleration","Wakefulness","Disinhibition","Suggestibility suppression","Cognitive euphoria","Compulsive redosing","Mania"],"Physical Effects":["Increased libido","Stamina enhancement","Stimulation","Appetite suppression","Dehydration","Dry mouth","Restless legs","Shakiness","Teeth grinding","Abnormal heartbeat","Increased blood pressure","Increased heart rate","Vasoconstriction"],"Visual Effects":[]},"Therapeutic Uses":"Attention Deficit Disorder with Hyperactivity","Title":"Lisdexamphetamine","UNII":"H645GUL8KJ","Wikipedia":"Eticyclidine","XLogP":1.2}